Physiological incompatibilities of porcine hepatocytes for clinical liver support

Liver Transplantation

Volumn 12, Issue 12, 2006, Pages 1832-1840

  Schrem, Harald ^a   Kleine, Moritz ^a   Borlak, Jürgen ^b   Klempnauer, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYTESTOSTERONE; 6ALPHA HYDROXYTESTOSTERONE; 7ALPHA HYDROXYTESTOSTERONE; ALBUMIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CREACTIVE PROTEIN; INTERLEUKIN 6; MESSENGER RNA; TESTOSTERONE; TESTOSTERONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; XENOBIOTIC AGENT;

ADULT; AGED; ANIMAL CELL; ARTICLE; BIOARTIFICIAL LIVER; CELL FUNCTION; CELL ISOLATION; CELL METABOLISM; COCULTURE; COMPETENCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CULTURE; LIVER FAILURE; LIVER SUPPORT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SPECIES DIFFERENCE; SWINE; TESTOSTERONE METABOLISM;

AGED; ANIMALS; C-REACTIVE PROTEIN; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION; HEPATOCYTES; HISTOCOMPATIBILITY; HUMANS; INTERLEUKIN-6; LIVER, ARTIFICIAL; MALE; MIDDLE AGED; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SWINE; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845492372     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20918     Document Type: Article

References (43)

1. O'Grady J. Bioartificial liver in acute liver failure: Impostor or simply misunderstood? Hepatology 2005;41:383-385.
2. White DJ, Yannoutsos N. Production of pigs transgenic for human DAF to overcome complement-mediated hyperacute xenograft rejection in man. Res Immunol 1996;147:88-94.
3. Hara H, Ezzelarab M, Rood PP, Lin YJ, Busch J, Ibrahim Z, et al. Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation 2006:13:357-365.
4. Levy MF, Crippin J, Sutton S, Netto G, McCormack J, Curiel T, et al. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. Transplantation 2000;69:272-280.
5. Makowka L, Cramer DV, Hoffman A, Breda M, Sher L, Eiras-Hreha G, et al. The use of a pig xenograft for temporary support for a patient with fulminant hepatic failure. Transplantation 1995;59:1654-1659.
6. Horslen SP, Hammel JM, Fristoe LW, Kangas JA, Collier DS, Sudan DL, et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000;70:1472-1478.
7. Kuddus R, Patzer JF 2nd, Lopez R, Mazariegos GV, Meighen B, Kramer DJ, Rao AS. Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 2002;73:420-429.
8. Sauer IM, Kardassis D, Zeillinger K, Pascher A, Gruenwald A, Pless G, et al. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells. Xenotransplantation 2003;10:460-469.
9. Irgang M, Sauer IM, Karlas A, Zeilinger K, Gerlach JC, Kurth R, et al. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clin Virol 2003:28:141-154.
10. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667; discussion 667-670.
11. Ichai P, Samuel D. Treatment of patients with hepatic failure: the difficult place of liver support systems. J Hepatol 2004;41:694-695.
12. Hughes RD, Nicolaou N, Langley PG, Ellis AJ, Wendon JA, Williams R. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artif Organs 1998; 22:854-858.
13. Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, et al. TNF alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000;119:446-460.
14. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340: 448-454.
15. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev 2002;54:129-158.
16. Luedde T, Liedtke C, Manns MP, Trautwein C. Losing balance: cytokine signaling and cell death in the context of hepatocyte injury and hepatic failure. Eur Cytokine Netw 2002;13:377-383.
17. Pauli U, Beutler B, Peterhans E. Porcine tumor necrosis factor alpha: cloning with the polymerase chain reaction and determination of the nucleotide sequence. Gene 1989; 81:185-191.
18. Kuhnert P, Wuthrich C, Peterhans E, Pauli U. The porcine tumor necrosis factor-encoding genes: sequence and comparative analysis. Gene 1991;102:171-178.
19. Richards CD, Saklatvala J. Molecular cloning and sequence of porcine interleukin 6 cDNA and expression of mRNA in synovial fibroblasts in vitro. Cytokine 1991;3:269-276.
20. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev 2004:56:291-330.
21. Schon MR, Kollmar O, Wolf S, Schrem H, Matthes M, Akkoc N, et al. Liver transplantation after organ preservation with normothermic extracorporeal perfusion. Ann Surg 2001;233:114-123.
22. Borlak J, Hock A, Hansen T, Richter E. DNA adducts in cultures of polychlorinated biphenyl-treated human hepatocytes. Toxicol Appl Pharmacol 2003;188:81-91.
23. Dunn JCY, Yarmush ML, Koebe HG, Tompkins RG. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J 1989; 3:175-176.
24. Bader A, Borel Rinkes IH, Closs EI, Ryan CM, Toner M, Cunningham JM, et al. A stable long-term hepatocyte culture system for studies of physiologic processes: cytokine stimulation of the acute phase response in rat and human hepatocytes. Biotechnol Prog 1992;8:219-225.
25. Mueller AR, Platz KP, Haak M, Undi H, Muller C, Kottgen E, et al. The release of cytokines, adhesion molecules, and extracellular matrix parameters during and after reperfusion in human liver transplantation. Transplantation 1996;62:1118-1126.
26. Niehof M, Streetz K, Rakemann T, Bischoff SC, Manns MP, Horn F, Trautwein C. Interleukin-6-induced tethering of STAT3 to the LAP/C/ EBPß promoter suggests a new mechanism of transcriptional regulation by STAT3. J Biol Chem 2000;276:9016-9027.
27. Thum T, Haverich A, Borlak J. Cellular dedifferentiation of endothelium is linked to activation and silencing of certain nuclear transcription factors: implications for endothelial dysfunction and vascular biology. FASEB J 2000:14:740-749.
28. Schrödl W, Kunze R, Krüger M. [Determination of C-reactive protein and neopterin in serum of diseased and bacterially infected swine]. Berl Munch Tierarztl Wochenschr 1998;111:321-325. [Ger]
29. Arlotto MP, Trant JM, Estabrook RW. Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods Enzymol 1991;206:454-462.
30. Thum T, Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 2002;16:1537-1549.
31. Pietrangelo A, Shafritz DA. Homeostatic regulation of hepatocyte nuclear transcription factor 1 expression in cultured hepatoma cells. Proc Natl Acad Sci USA 1994;91: 182-186.
32. Trautwein C, Rakemann T, Pietrangelo A, Plumpe J, Montosi G, Manns MP. C/ EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration. J Biol Chem 1996;271:22262-22270.
33. Alam T, An MR, Papaconstantinou J. Differential expression of three C/ EBP isoforms in multiple tissues during the acute phase response. J Biol Chem 1992;267:5021-5024.
34. Welm AL, Mackey SL, Timchenko LT, Darlington GJ, Timchenko NA. Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/ enhancer binding protein alpha mRNA. J Biol Chem 2000;275:27406-27413.
35. Buck M, Zhang L, Halasz NA, Hunter T, Chojkier M. Nuclear export of phosphorylated C/EBPbeta mediates the inhibition of albumin expression by TNF-alpha. EMBO J 2001;20:6712-6723.
36. Yin M, Yang SQ, Lin HZ, Lane MD, Chatterjee S, Diehl AM. Tumor necrosis factor alpha promotes nuclear localization of cytokine-inducible CCAAT/ enhancer binding protein isoforms in hepatocytes. J Biol Chem 1996;271:17974-17978.
37. Ablij H, Meinders A. C-reactive protein: history and revival. Eur J Intern Med 2002:13:412.
38. Szalai AJ. The biological functions of C-reactive protein. Vascul Pharmacol 2002:39:105-107.
39. Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin WH Jr. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 2000;68:5652-5656.
40. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-747.
41. Harlow GR, Halpert JR. Mutagenesis study of Asp-290 in cytochrome P450 2B11 using a fusion protein with rat NADPH-cytochrome P450 reductase. Arch Biochem Biophys 1996;326:85-92.
42. Gerlach JC, Zeilinger K, Sauer IM, Mieder T, Naumann G, Grunwald A, et al. Extracorporeal liver support: porcine or human cell based systems? Int J Artif Organs 2002;25: 1013-1018.
43. Mitry RR, Hughes RD, Dhawan A. Progress in human hepatocytes: isolation, culture & cryopreservation. Semin Cell Dev Biol 2002;13:463-467.